Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| agout-protein; neuropeptide Y |
|
Definition
|
|
Term
|
Definition
|
|
Term
| effects on MC1R receptor, decreases food intake and increases energy expenditure |
|
Definition
|
|
Term
| antihistamines, antiepileptics, antihypertensives, antidepressants, corticosteroids, diabetic, antipsychotics |
|
Definition
| Associated with weight gain |
|
|
Term
| exercise: 30-45 minutes, 3-5 days per week |
|
Definition
|
|
Term
| exercise: 30 or more minutes, most, if not all days of the week |
|
Definition
|
|
Term
| Inhibits fat absorption from intestines, inhibitor of pancreatic enzyme, lipase |
|
Definition
|
|
Term
| 5-HT2C receptor agonist: anorexigenic (decreases food consumption and promotes satiety) |
|
Definition
|
|
Term
| AE include nausea, dry mouth, nausea, dizzness, headache, vomiting, fatigue, urinary tract infections |
|
Definition
|
|
Term
| FDA approved for long-term use |
|
Definition
| Orlistat (Xenical) and Phentermine-topiramate (Qsymia) |
|
|
Term
| Lack of long term efficacy; hypertension, toxicity |
|
Definition
| Stimulants (ex. Phentermine) |
|
|
Term
| Addresses obsessive impulsive aspect of eating disorders- |
|
Definition
|
|
Term
| suppresses appetite via 5HT2C antagonistic properties |
|
Definition
|
|
Term
| also may be used in obesity |
|
Definition
| Metformin, Anticonvulsants |
|
|
Term
| synthetic peptide hormone; modulates gastric emptying, prevents postprandial risk in plasma glucagan = satiety; being tested for obesity |
|
Definition
|
|
Term
| CB1 Receptor antagonist thought to suppress appetite; withdrawn NDA for weight management; suicide ideation and other psychiatric symptoms |
|
Definition
|
|
Term
| complications include infection, DVT, wound deshicense, anastomotic leaks... irritable bowel syndrome can lead to rectal problems |
|
Definition
|
|
